Medical Law in Japan

Overview of the Regulatory Framework

Japanese medical law operates at the intersection of public health regulation, constitutional rights, and private tort liability. The foundational statutes are the Medical Practitioners’ Act (Ishi Hō, 1948) and the Medical Care Act (Iryō Hō, 1948). The Medical Practitioners’ Act establishes the licensing regime for physicians, requiring graduation from an accredited medical school, passage of the National Medical Examination, and registration with the Ministry of Health, Labour and Welfare. The Medical Care Act governs the organisation of healthcare services, the regulation of hospitals and clinics, and the obligation of prefectural governments to develop regional healthcare plans.

The universal health insurance system comprises three principal statutes: the Health Insurance Act (Kenkō Hoken Hō, 1922), covering employees of private enterprises; the National Health Insurance Act (Kokumin Kenkō Hoken Hō, 1958), covering self-employed persons and pensioners; and the Employees’ Pension Insurance Act. Every legal resident is required to enrol, with co-payment rates of 30% for most adults (reduced to 20% for children and 10% for the elderly). The Central Social Insurance Medical Council (Chūikyō) sets the fee schedule for all medical procedures, effectively functioning as a national price control mechanism.

The Doctrine of Informed Consent

Japanese courts have recognised the physician’s duty to obtain informed consent as rooted in the right to self-determination derived from Article 13 of the Constitution. The Supreme Court addressed this doctrine in two landmark decisions. In the Tokyo University Neurosurgery Case (Saikō Saibansho, 2001), the Court held that a physician must explain the diagnosis, the nature of treatment, expected benefits and risks, and available alternatives, including the option of no treatment. The patient had suffered permanent neurological damage following brain surgery; the Court found the physician failed to adequately disclose the risk of paralysis.

In the Yokohama City University Case (Saikō Saibansho, 2003), the Court extended the doctrine to encompass alternative treatment modalities, holding that even where a standard treatment exists, the physician must disclose reasonable alternatives carrying materially different risk profiles. The scope of disclosure is measured by a “reasonable physician” standard, adjusted for the patient’s circumstances and the urgency of the situation. Exceptions include emergencies, therapeutic privilege (where disclosure would cause serious psychological harm), and waiver by the patient; these are construed narrowly, with the burden of proof on the physician.

Medical Malpractice Litigation

Medical malpractice claims sound in tort under Civil Code Articles 709 (general tort liability) and 715 (vicarious liability). The plaintiff must establish a physician-patient relationship, breach of the duty of care, causation, and quantifiable damages. The burden of proof on causation is the most significant hurdle. Courts traditionally require proof to a standard approximating “more likely than not” (the shin’ni itaru standard). However, some courts have applied the “proportional likelihood of causation” theory (sōtō inga) where the defendant’s negligence demonstrably increased the risk of harm, shifting the burden to the defendant to rebut the inference.

A notable development is the rise of criminal prosecutions of physicians for medical errors. The Fukushima Prefectural Hospital Case (Fukushima District Court, 2004), in which an obstetrician was convicted of professional negligence following a delayed emergency caesarean section, exemplifies this trend. Critics argue that criminalisation deters reporting and undermines patient safety. The Japan Association of Obstetricians and Gynaecologists has documented a marked decline in physicians willing to practise high-risk obstetrics.

Clinical Research and Pharmaceutical Regulation

The Clinical Trials Act (Rinshō Shiken Hō, 2018) introduced comprehensive regulation of clinical research, requiring prior approval from a Certified Review Board, public registration, and informed consent with specific disclosure requirements. Pharmaceutical regulation is governed by the Pharmaceuticals and Medical Devices Act. The Pharmaceuticals and Medical Devices Agency (PMDA) conducts scientific review of new drugs and devices, monitors post-market safety, and operates the adverse drug reaction reporting system. The PMDA follows a two-tier review structure: standard (approximately twelve months) and priority (approximately nine months) for drugs addressing unmet medical needs.

End-of-Life Decision-Making

Japan lacks specific legislation on euthanasia and physician-assisted suicide. The Tokai University Case (Yokohama District Court, 1995) established the first judicial framework for passive euthanasia, requiring: (1) incurable terminal disease; (2) the patient’s voluntary and consistent wish for discontinuation; (3) limitation to life-sustaining measures; and (4) medically acceptable methods. The Kawasaki Kyodo Hospital Case (Yokohama District Court, 2009) refined these conditions, emphasising that patient intent must be clearly established through advance directives or reliable family testimony, and addressed the role of hospital ethics committees in reviewing such decisions.

Organ Transplantation

The Organ Transplant Act (Zōki Ishoku Hō, 1997, revised 2010) initially permitted organ donation from brain-dead donors only with the deceased’s written consent and no family objection. This resulted in exceptionally low donation rates — fewer than fifty brain-dead donations annually. The 2010 revision liberalised the regime by allowing donation with family consent alone, provided the deceased had not previously expressed opposition, and lowered the minimum age from fifteen to twelve years. Despite these reforms, donation rates remain low due to cultural resistance to brain-death criteria.